Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.52 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.51 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | F9 | P00740 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210538 | 0.80 | NPC1 (0.50) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6217001 | 0.75 | CYSLTR1 (0.50) | — | |
| SCHEMBL1196687 | 0.73 | CCR5 (0.64) | KMT2A | |
| SCHEMBL6212464 | 0.73 | CCR5 (0.47) | KMT2AMEN1SMN1; SMN2MAPTPKM | |
| SCHEMBL30354843 | 0.72 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14777208 | 0.72 | NPC1 (0.67) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6214742 | 0.72 | CCR5 (0.62) | KMT2A | |
| SCHEMBL25382938 | 0.72 | NPC1 (0.74) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30354845 | 0.72 | NPC1 (0.74) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20370634 | 0.71 | MAPT (1.00) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | NPC1 3627/4885RAB9A 4142/4885KMT2A 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.